Corbus Pharmaceuticals Holdings (CRBP) Current Assets (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Current Assets of $167.0 million for Q4 2025, up 9.14% year-over-year from $153.0 million in Q4 2024, and up 55.2% quarter-over-quarter from $107.6 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Current Assets (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Current Assets history runs 13 years deep, the most recent figure standing at $167.0 million for Q4 2025.
- In Q4 2025, Current Assets rose 9.14% year-over-year to $167.0 million; the TTM figure through Dec 2025 stood at $167.0 million (up 9.14% YoY), while the FY2025 annual figure was $167.0 million, up 9.14% from the prior year.
- Current Assets for Q4 2025 stood at $167.0 million, up from $107.6 million in the prior quarter.
- The five-year high for Current Assets was $167.0 million in Q4 2025, with the low at $23.5 million in Q4 2023.
- The 5-year median for Current Assets is $109.6 million (2021), against an average of $100.1 million.
- The sharpest annual moves came in 2023 and 2024: Current Assets plunged 60.87% in 2023, then surged 549.69% in 2024.
- Corbus Pharmaceuticals Holdings' Current Assets stood at $100.2 million in 2021, then slumped by 39.94% to $60.2 million in 2022, then slumped by 60.87% to $23.5 million in 2023, then soared by 549.69% to $153.0 million in 2024, then rose by 9.14% to $167.0 million in 2025.
- Business Quant data shows CRBP's Current Assets at $167.0 million in Q4 2025, $107.6 million in Q3 2025, and $122.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | 166.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 166.95 Mn |
| Sep 30, 2025 | 107.57 Mn |
| Jun 30, 2025 | 122.83 Mn |
| Mar 31, 2025 | 137.36 Mn |
| Dec 31, 2024 | 152.98 Mn |
| Sep 30, 2024 | 160.89 Mn |
| Jun 30, 2024 | 148.31 Mn |
| Mar 31, 2024 | 121.70 Mn |
| Dec 31, 2023 | 23.55 Mn |
| Sep 30, 2023 | 31.21 Mn |
| Jun 30, 2023 | 38.27 Mn |
| Mar 31, 2023 | 45.86 Mn |
| Dec 31, 2022 | 60.18 Mn |
| Sep 30, 2022 | 67.35 Mn |
| Jun 30, 2022 | 75.24 Mn |
| Mar 31, 2022 | 88.48 Mn |
| Dec 31, 2021 | 100.20 Mn |
| Sep 30, 2021 | 111.67 Mn |
| Jun 30, 2021 | 111.58 Mn |
| Mar 31, 2021 | 130.29 Mn |